0. Results and discussion Statistical results Univariate analysis The individual fitness levels measured in Watt/kg bodyweight

GDC-973 at time points T1, T2 and T3, and stratified by study group, are illustrated in Figure 1. As one can see from the graph, two athletes of the control group show normal increases of their values at time point T2, but are followed by implausible deep declines at time point T3. The drop in physical performance was due to an infection, therefore the two individuals are considered to be protocol non-compliers, and the corresponding records are dropped from computations, otherwise these two data would have had a quite negative impact of the performance of the placebo group and would

have created a wrong and too positive difference in performance towards the Ubiquinol supplement group. Thus, in total n = 50 athletes of the experimental group and n = 48 athletes of the control group finally remained for further analysis. Figure 1 Individual physical fitness by time point and study group. Individual performance output measured in W/kg bw at time points T1, T2 and T3, stratified by placebo group (Control group) and Ubiquinol group (Experimental group). The arithmetic means of the power output measurements increased from 3.70 W/kg bodyweight (±0.56) at time point T1 to 4.08 W/kg bodyweight (±0.48) at time point T3 in the experimental group and from 3.64 W/kg bw (± 0.49) to 3.94 W/kg bw (±0.47) in the control group, respectively (Figure 2). This corresponds to mean PI3K phosphorylation differences MG-132 order between the time points T1 and T3 of 0.38 W/kg bodyweight

{Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|buy Anti-infection Compound Library|Anti-infection Compound Library ic50|Anti-infection Compound Library price|Anti-infection Compound Library cost|Anti-infection Compound Library solubility dmso|Anti-infection Compound Library purchase|Anti-infection Compound Library manufacturer|Anti-infection Compound Library research buy|Anti-infection Compound Library order|Anti-infection Compound Library mouse|Anti-infection Compound Library chemical structure|Anti-infection Compound Library mw|Anti-infection Compound Library molecular weight|Anti-infection Compound Library datasheet|Anti-infection Compound Library supplier|Anti-infection Compound Library in vitro|Anti-infection Compound Library cell line|Anti-infection Compound Library concentration|Anti-infection Compound Library nmr|Anti-infection Compound Library in vivo|Anti-infection Compound Library clinical trial|Anti-infection Compound Library cell assay|Anti-infection Compound Library screening|Anti-infection Compound Library high throughput|buy Antiinfection Compound Library|Antiinfection Compound Library ic50|Antiinfection Compound Library price|Antiinfection Compound Library cost|Antiinfection Compound Library solubility dmso|Antiinfection Compound Library purchase|Antiinfection Compound Library manufacturer|Antiinfection Compound Library research buy|Antiinfection Compound Library order|Antiinfection Compound Library chemical structure|Antiinfection Compound Library datasheet|Antiinfection Compound Library supplier|Antiinfection Compound Library in vitro|Antiinfection Compound Library cell line|Antiinfection Compound Library concentration|Antiinfection Compound Library clinical trial|Antiinfection Compound Library cell assay|Antiinfection Compound Library screening|Antiinfection Compound Library high throughput|Anti-infection Compound high throughput screening| (±0.22) in the experimental group and of 0.30 W/kg bodyweight (±0.18) in the control group. Accordingly, the mean percentage increases at time point T3 calculated with respect to time point T1 are 11.0% (±8.2) in the experimental (ubiquinol) group and 8.5% (±5.7) in the control (placebo) group. For both study groups, the calculated statistical parameters are summed up in Table 1. Figure 2 Mean Measured fitness by time point and study group. Progress of fitness (absolute values in W/kg bw and percentage values) at time points T1, T2 and T3 plotted as means and one standard deviation, stratified by study group. Table 1 Summary Statistics Parameter Experimental group N Mean 95% CI Std Min Med Max T1 50  3.70 3.54-3.86 0.56 2.14 3.77 4.88 T2 50  3.81 3.66-3.96 0.53 2.65 3.90 4.92 T3 50  4.08 3.94-4.21 0.48 2.85 4.24 4.99 Diff. abs. T1-T3 50  0.38 0.32-0.44 0.22 0.07 0.34 1.13 Diff. perc. T1-T3 50 11.03 8.71-13.55 8.16 1.62 8.58 41.09 Parameter Control group N Mean 95% CI Std Min Med Max T1 48  3.64 3.50-3.78 0.49 2.42 3.86 4.28 T2 48  3.75 3.60-3.89 0.49 2.72 3.89 4.38 T3 48  3.94 3.80-4.07 0.47 2.80 4.08 4.52 Diff.